Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. Show More...
-
Website http://www.beamtx.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 15.83 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -3.34 -2.01 -2.16 Dividends USD Payout Ratio % * Shares Mil 35.0 45.0 49.0 Book Value Per Share * USD 5.08 Free Cash Flow Per Share * USD Return on Assets % -136.07 -56.35 -32.92 Financial Leverage (Average) 1.23 Return on Equity % -40.63 Return on Invested Capital % -36.61 Interest Coverage -417.86 Current Ratio 5.79 3.24 8.26 Quick Ratio 5.72 3.15 8.06 Debt/Equity 0.11